-
Mashup Score: 0Prognostic biomarkers and staging in AL amyloidosis - 3 year(s) ago
In this second article of the ‘Amyloidosis Series’, we will discuss the prognosis and risk stratification models for AL amyloidosis and summarize the best current practices for patient evaluation.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Editorial theme | Incidence and diagnosis of AL amyloidosis - 3 year(s) ago
Amyloidosis refers to a rare and heterogeneous group of hematological disorders characterized by extracellular proliferation of proteins in tissues and organs to form insoluble fibrils, leading to organ failure.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Jonas Wixner, MD, PhD, Umeå University, Umeå, Sweden, discusses his ISA 2020 talk on 99mTc-DPD scintigraphy and how it predicts…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Genetic signatures & hereditary ATTR amyloidosis - 4 year(s) ago
Joel Buxbaum, MD, Scripps Research, La Jolla, CA, discusses in detail the genetic signatures associated with hereditary ATTR amyloidosis. Specifically…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0AL amyloidosis during the pandemic - 4 year(s) ago
Systemic light-chain (AL) amyloidosis is a multi-system disease and therefore can implicate a large variety of organ systems. COVID-19 is…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0New organ response criteria in amyloidosis diagnosis - 4 year(s) ago
Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses the diagnostic criteria for amyloidosis, outlining the new organ response criteria….
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Auto-HSCT in AL amyloidosis - 4 year(s) ago
Autologous stem cell transplant (ASCT) has been utilized in the management of immunoglobulin light chain (AL) amyloidosis for several decades….
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1ANDROMEDA study: updated safety run-in results - 4 year(s) ago
The Phase III ANDROMEDA (NCT03201965) study investigated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for patients with…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Kidney transplantation in AL amyloidosis & monoclonal immunoglobulin deposition disease - 4 year(s) ago
Nelson Leung, MD, Mayo Clinic, Rochester, MN, discusses kidney transplantation in immunoglobulin light chain (AL) amyloidosis and monoclonal immunoglobulin deposition…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Heart transplantation in ATTR amyloidosis - 4 year(s) ago
Mathew Maurer, MD, Columbia University, New York, NY, discusses his talk on heart transplantation in ATTR amyloidosis. This interview was…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The @MM_Hub is reviewing the management and treatment of AL #amyloidosis. In the 2nd article of this #EditorialTheme, you can check the staging systems and new prognostic #biomarkers being studied for AL amyloidosis #isa2020 #ash20 #mmsm #hematology https://t.co/4LJEuPqGS9